Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Rossana Maffei, Stefania Fiorcari, Silvia Martinelli, Stefania Benatti, Jenny Bulgarelli, Lara Rizzotto, Giulia Debbia, Rita Santachiara, Gian Matteo Rigolin, Francesco Forconi, Davide Rossi, Luca Laurenti, Giuseppe A. Palumbo, Daniele Vallisa, Antonio Cuneo, Gianluca Gaidano, Mario Luppi, Roberto Marasca

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)


Lenalidomide is a therapeutically effective drug in chronic lymphocytic leukemia (CLL). Twenty-seven CLL patients were treated with lenalidomide in a phase II clinical trial. Ten patients were grouped as responders (R) and 6 as nonresponders (NR). We evaluated T lymphocytes, NK, monocytes and dendritic cells at baseline and after treatment. A gene expression analysis was performed on 16 CLL samples collected before treatment. The levels of immune cells or immune-related cytokines are not different between R and NR patients. However, CLL patients sensitive to lenalidomide clearly show a peculiar gene expression profile in leukemic cells. The most up-regulated gene (fold change = +23 in R vs. NR) is Wnt inhibitor SHISA homolog 3 (SHISA3). SHISA3highCLL are characterized by a restrained activation of Wnt signaling and sensibility to lenalidomide-induced apoptosis. In conclusion, SHISA3 is a candidate gene for the identification of CLL patients who will benefit of lenalidomide treatment as single agent.
Lingua originaleEnglish
pagine (da-a)423-433
Numero di pagine11
Stato di pubblicazionePubblicato - 2018


  • Cancer Research
  • Chronic lymphocytic leukemia
  • Hematology
  • Oncology
  • SHISA3
  • Wnt signaling
  • clinical response
  • lenalidomide


Entra nei temi di ricerca di 'Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide'. Insieme formano una fingerprint unica.

Cita questo